Skip to main content
. 2019 Sep 6;9:873. doi: 10.3389/fonc.2019.00873

Table 1.

Pre-clinical and clinical studies with Tα1 in cancer and chronic hepatitis B and C.

Pathology Study Treatment Efficacy References
Melanoma Pre-clinical Tα1 monotherapy Evidence of treatment efficacy (15, 30)
No significant evidence of treatment efficacy (1719, 31, 3335)
Tα1 in combination therapy with:
αβ-IFN
IL-2
Cy and αβ-IFN
anti-PD-1 Ab

Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
(1719)
(19)
(20)
(30)
Tα1 fusion proteins:
- concatemer
- thymopentin
- RGDR
- iRGD
- Fc
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
(31)
(32)
(33)
(34)
(35)
Clinical Tα1 in combination therapy with:
- dacarbazine and IL-2
- dacarbazine and IFNα
- dacarbazine and IFNα
- dacarbazine
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
(25)
(26)
(27, 29)
(28, 29)
Chronic hepatitis B Clinical Tα1 monotherapy Evidence of treatment efficacy (40, 4244)
No evidence of treatment efficacy (46, 47)
Tα1 in combination therapy with:
- IFNα
- pegylated IFNα
- famciclovir
- lamivudine
- entecavir
Evidence of treatment efficacy
No evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
No evidence in HBV-related compensated cirrhosis
(4851)
(52)
(62)
(63)
(64)
(65)
Chronic hepatitis C Clinical Tα1 monotherapy No evidence of treatment efficacy (54, 55)
Tα1 in combination therapy with:
- IFNα
- IFN and ribavirin
Evidence of treatment efficacy
Evidence of treatment efficacy
No evidence in on-treatment viral response
(53, 5658)
(6669)
(70)
HCC Clinical Tα1 monotherapy Evidence of treatment efficacy (71, 72)
Tα1 in combination therapy with:
- TACE
- lamivudine
- sorafenib
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
(7375)
(76)
(77)
Lung cancer Pre-clinical Tα1 monotherapy Evidence of treatment efficacy (19, 8587, 89)
No significant evidence of treatment efficacy (17, 24, 34, 80, 84)
Tα1 in combination therapy with:
- αβ-IFN
- Cy and αβ-IFN
- Cy and IL-2
- gemcitabine
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
Evidence of treatment efficacy
(17, 19)
(80)
(24)
(84)
Tα1 fusion protein:
- iRGD
Evidence of treatment efficacy (34)
Clinical Tα1 monotherapy Evidence of treatment efficacy (79)
Tα1 in combination therapy with:
- cisplatin, etoposide, IFNα2a
- ifosfamide, IFNα
- cisplatin, vinorelbine or gemcitabine
Evidence of treatment efficacy
Trend toward treatment efficacy
Evidence of treatment efficacy
(81)
(82)
(83)
HHS Vulnerability Disclosure